released the ICH E6(R3) draft guideline for public consultation in May 2023 in collaboration with global health authorities, including the FDA. The draft revises ICH E6(R2), and regulatory ...
Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
A second trial of a clot evacuation approach to remove a hematoma in spontaneous ICH has shown some encouraging results, despite a neutral primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback